Fig. 5From: A randomized, double-blind, placebo-controlled 12-week trial of infliximab in patients with juvenile-onset spondyloarthritisPercentage of patients reaching the Assessment of Spondyloarthritis international Society (ASAS) 20, 40, partial remission, and 5/6 response criteria per treatment group at week 12 (end RCT phase)Back to article page